news
MHRA approves Epidyolex® (cannabidiol) for TSC seizure treatment
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
List view / Grid view
Cannabinoids
news
Could medicinal cannabis be the answer to the opioid crisis?
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than any other medication, including opioids.
article
Ten recommendations to foster the UK’s medicinal cannabis market
In this article, EPR summarises the list of 10 recommendations for the UK Government, published by experts in the medicinal cannabis industry, to ensure the UK capitalises on the opportunities afforded by the market.
article
Why it’s high time for psychedelic drug development
Here, Dr Matthew McMurray and Dr J Andrew Jones of Miami University explain why psychedelic drugs are attracting R&D as potential treatments for neuropsychiatric and degenerative disorders and how their discovery of an in vivo production technique could enable further advancement.
news
CBD tablet significantly improves diabetic peripheral neuropathic pain
In a Phase II trial, a cannabidiol (CBD) sublingual tablet reduced pain scores in patients with diabetic peripheral neuropathy by approximately 50 percent.
news
Highest British business award goes to cannabis drug developer, GW Pharmaceuticals
The Queen’s Award for Enterprise in Innovation was awarded to GW for leadership in cannabinoid science and development of prescription cannabis-based medicines.
article
Measurement of heavy metals in cannabis vaping aerosols: a practical assessment
In light of the increased popularity of cannabis vaping in the United States, new regulations in the state of Colorado assert the need to test for heavy metal contaminants. Here, Robert Thomas explains the reasons for this pressing need and the challenges it presents.
news
FDA sends warning to companies selling unapproved CBD products
The warning letters were issued to two companies illegally selling over-the-counter cannabidiol (CBD) products for pain relief.
article
Carving out a slice of the European medical cannabis market
The European medical cannabis market lacks a common regulatory framework; Peter Kohut charts a route through the complexity and highlights opportunities for the taking.
![Jazz Pharmaceuticals Sign with Logo [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Jazz-pharmaceuticals-300x278.jpg)
![Jazz Pharmaceuticals Sign with Logo [Credit: Michael Vi / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Jazz-pharmaceuticals-e1612534960797.jpg)
news
Jazz to acquire GW Pharmaceuticals for $7.2 billion
According to Jazz Pharmaceuticals, the combined company will be a leader in neuroscience, well positioned to maximise the value of its diversified portfolio.
article
Cannabinoid series: medicinal cannabis and Brexit
Sarah Ellson from Fieldfisher spoke with European Pharmaceutical Review to discuss the position of medicinal cannabis in the UK and the impacts of Brexit.
news
CDMO awarded $850,000 contract for development of Acute Cannabinoid Overdose treatment
Under the contract, IRISYS LLC will develop a new, injectable formulation of drinabant that can rapidly and effectively reverse the symptoms of Acute Cannabinoid Overdose (ACO).
article
The Editors’ views: European Pharmaceutical Review’s 2020 round-up
Junior Editors of European Pharmaceutical Review, Hannah Balfour and Victoria Rees, discuss some of the most noteworthy news and announcements from this year.
article
Cannabinoid series: a CBD-inspired molecule to increase bioavailability
European Pharmaceutical Review spoke with Dean Petkanas from Neuropathix, formerly known as Kannalife, to find out why a CBD-inspired molecule can offer an improved therapeutic value.
article
Cannabinoid series: developing a synthetic CBD tablet
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.